CODX Stock Overview
A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.01 |
| 52 Week High | US$2.23 |
| 52 Week Low | US$1.00 |
| Beta | -0.85 |
| 11 Month Change | -18.55% |
| 3 Month Change | -42.29% |
| 1 Year Change | -10.62% |
| 33 Year Change | -89.44% |
| 5 Year Change | 13.47% |
| Change since IPO | -82.62% |
Recent News & Updates
Recent updates
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation
Jun 14
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
May 18A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Apr 14Co-Diagnostics: Hold Thesis Remains Well Intact
Sep 07Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes
Aug 11Co-Diagnostics spikes on shipments of monkeypox test
Jul 11Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Jul 06Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant
Jun 21Co-Diagnostics: Where's Eikon?
Apr 03Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate
Mar 28Co-Diagnostics: Swinging For The Fences
Jan 24Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?
Dec 28Why Co-Diagnostics Is A Solid Covid-19 Play
Aug 19Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Aug 14Shareholder Returns
| CODX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.7% | 1.5% | 2.2% |
| 1Y | -10.6% | 20.9% | 31.7% |
Return vs Industry: CODX underperformed the US Medical Equipment industry which returned 21.4% over the past year.
Return vs Market: CODX underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CODX volatility | |
|---|---|
| CODX Average Weekly Movement | 8.5% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CODX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CODX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 155 | Dwight Egan | www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Co-Diagnostics, Inc. Fundamentals Summary
| CODX fundamental statistics | |
|---|---|
| Market cap | US$33.85m |
| Earnings (TTM) | -US$41.28m |
| Revenue (TTM) | US$7.32m |
4.4x
P/S Ratio-0.8x
P/E RatioIs CODX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CODX income statement (TTM) | |
|---|---|
| Revenue | US$7.32m |
| Cost of Revenue | US$3.71m |
| Gross Profit | US$3.61m |
| Other Expenses | US$44.89m |
| Earnings | -US$41.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 49.30% |
| Net Profit Margin | -563.91% |
| Debt/Equity Ratio | 0% |
How did CODX perform over the long term?
See historical performance and comparison